Congress Called Xylazine a Public Health Threat in March. It Hasn't Voted Since.

On March 26, the Senate Judiciary Committee voted 19-3 to advance the Combating Illicit Xylazine Act — a bill with 99 House co-sponsors and 29 Senate co-sponsors, backed by the American Veterinary Medical Association, that would finally give xylazine a formal place in the Controlled Substances Act as a Schedule III drug, with carve-outs so vets, farmers, and ranchers can keep using it legally. The bill is still sitting there. Five months, no full Senate floor vote.

A bill can have 128 co-sponsors and 90% committee support and still not be the fastest-moving thing in this story — the drug supply is.

Xylazine, the veterinary sedative that turned “tranq” into a household word for the wounds it leaves behind, isn’t waiting on Congress to decide what to do about it. Medetomidine — another veterinary sedative, chemically different but functionally similar — has already started replacing it as a fentanyl-supply adulterant in several East Coast cities. It’s not covered by the bill sitting in the Senate at all, because you can’t legislate against a substitute nobody had written the law around yet. This is the same shape of problem the DEA hit with fentanyl analogs in 2018 and is hitting again with designer benzodiazepines this year: name one molecule, and the market’s next move is already the molecule you didn’t name.

None of that is an argument against passing the bill. Scheduling xylazine still matters — it standardizes penalties for trafficking, unlocks funding categories tied to controlled-substance status, and gives prosecutors and public health officials a clearer legal floor to work from. It’s just not, on its own, a fix for the underlying chase. The people showing up to wound care clinics with xylazine-associated ulcers this week are being treated for a drug that may already be secondary to what’s actually in this month’s supply, in cities where nobody’s tested for medetomidine yet because the testing infrastructure follows the legislation, not the other way around.

Congress moved fast enough to get a bipartisan bill out of committee by a 6-to-1 margin. It hasn’t moved fast enough to get it to a vote. The gap between those two speeds is where the next drug gets its start.